Physician profile
Lauren E Bock
NPI 1578754982
$678.17
in general payments reported to CMS, 2019-2025
11 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $241 · 2023: $23.96 · 2024: $119 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $119.09 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $117.84 | 2022-2025 | Lokelma |
| Novo Nordisk INC | $110.94 | 2023-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $81.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.31 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $62.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.31 | 2022 | |
| Esperion Therapeutics, INC. | $15.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.